Literature DB >> 11415463

Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells.

M Kortylewski1, P C Heinrich, M E Kauffmann, M Böhm, A MacKiewicz, I Behrmann.   

Abstract

The mitogen-activated protein kinases (MAPKs) extracellular signal-regulated protein kinase (ERK)1 and ERK2, involved in regulating cell growth and differentiation, are constitutively active in A375 and WM239 human melanoma cells. Using PD098059, an inhibitor of MAPK kinase (MEK), we investigated the role of persistently activated ERK1/2 in cell growth. The inhibition of MAPK activity induced a dose-dependent growth arrest in G(0)/G(1) phase. Correspondingly, we observed the up-regulation of the cyclin-dependent kinase (Cdk) inhibitor p27/Kip1 and hypophosphorylation of the retinoblastoma protein. Further studies showed that PD098059 treatment significantly decreased Cdk2 kinase activity, most probably owing to an augmented level of p27/Kip1 associated with cyclin E-Cdk2 complexes. The accumulation of p27/Kip1 protein in A375 cells was attributed to its increased stability. Our findings suggest that constitutively active ERK1/2 kinases contribute to the growth of melanoma cells by negative regulation of the p27/Kip1 inhibitor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11415463      PMCID: PMC1221955          DOI: 10.1042/0264-6021:3570297

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  26 in total

1.  Specificity and mechanism of action of some commonly used protein kinase inhibitors.

Authors:  S P Davies; H Reddy; M Caivano; P Cohen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

2.  Novel Ras antagonist blocks human melanoma growth.

Authors:  B Jansen; H Schlagbauer-Wadl; H Kahr; E Heere-Ress; B X Mayer; H Eichler; H Pehamberger; M Gana-Weisz; E Ben-David; Y Kloog; K Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

3.  Transformation of mammalian cells by constitutively active MAP kinase kinase.

Authors:  S J Mansour; W T Matten; A S Hermann; J M Candia; S Rong; K Fukasawa; G F Vande Woude; N G Ahn
Journal:  Science       Date:  1994-08-12       Impact factor: 47.728

4.  Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1.

Authors:  P Henriet; Z D Zhong; P C Brooks; K I Weinberg; Y A DeClerck
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

5.  Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells.

Authors:  G Baldassarre; B Belletti; P Bruni; A Boccia; F Trapasso; F Pentimalli; M V Barone; G Chiappetta; M T Vento; S Spiezia; A Fusco; G Viglietto
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

6.  Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.

Authors:  K Polyak; M H Lee; H Erdjument-Bromage; A Koff; J M Roberts; P Tempst; J Massagué
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

7.  Differential expression of ras oncogene products among the types of human melanomas and melanocytic nevi.

Authors:  H Yasuda; H Kobayashi; A Ohkawara; N Kuzumaki
Journal:  J Invest Dermatol       Date:  1989-07       Impact factor: 8.551

8.  Ras mutations in human melanoma: a marker of malignant progression.

Authors:  N J Ball; J J Yohn; J G Morelli; D A Norris; L E Golitz; J P Hoeffler
Journal:  J Invest Dermatol       Date:  1994-03       Impact factor: 8.551

9.  Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype.

Authors:  A P Albino; G Sozzi; D M Nanus; S C Jhanwar; A N Houghton
Journal:  Oncogene       Date:  1992-11       Impact factor: 9.867

10.  Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma.

Authors:  M Jafari; T Papp; S Kirchner; U Diener; D Henschler; G Burg; D Schiffmann
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more
  22 in total

1.  ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets.

Authors:  Jessie Villanueva; Yuval Yung; Janice L Walker; Richard K Assoian
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

Review 2.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

3.  Fcgamma receptor cross-linking stimulates cell proliferation of macrophages via the ERK pathway.

Authors:  Yong Luo; Jeffrey W Pollard; Arturo Casadevall
Journal:  J Biol Chem       Date:  2009-12-08       Impact factor: 5.157

4.  Tumor suppressor p53 status does not determine the differentiation-associated G₁ cell cycle arrest induced in leukemia cells by 1,25-dihydroxyvitamin D₃ and antioxidants.

Authors:  Thelma Thompson; Michael Danilenko; Lyubomir Vassilev; George P Studzinski
Journal:  Cancer Biol Ther       Date:  2010-08-13       Impact factor: 4.742

5.  Glioma-specific cation conductance regulates migration and cell cycle progression.

Authors:  Arun K Rooj; Carmel M McNicholas; Rafal Bartoszewski; Zsuzsanna Bebok; Dale J Benos; Catherine M Fuller
Journal:  J Biol Chem       Date:  2011-11-30       Impact factor: 5.157

Review 6.  Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place?

Authors:  Ahmed Lasfar; Karine A Cohen-Solal
Journal:  Carcinogenesis       Date:  2010-07-23       Impact factor: 4.944

Review 7.  p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Authors:  Seth A Wander; Dekuang Zhao; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2010-10-21       Impact factor: 12.531

Review 8.  Overcoming resistance to BRAF inhibitors.

Authors:  Imanol Arozarena; Claudia Wellbrock
Journal:  Ann Transl Med       Date:  2017-10

9.  Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.

Authors:  Ludovica Ciuffreda; Donatella Del Bufalo; Marianna Desideri; Cristina Di Sanza; Antonella Stoppacciaro; Maria Rosaria Ricciardi; Sabina Chiaretti; Simona Tavolaro; Barbara Benassi; Alfonso Bellacosa; Robin Foà; Agostino Tafuri; Francesco Cognetti; Andrea Anichini; Gabriella Zupi; Michele Milella
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

10.  p27 suppresses cyclooxygenase-2 expression by inhibiting p38β and p38δ-mediated CREB phosphorylation upon arsenite exposure.

Authors:  Xun Che; Jinyi Liu; Haishan Huang; Xiaoyi Mi; Qing Xia; Jingxia Li; Dongyun Zhang; Qingdong Ke; Jimin Gao; Chuanshu Huang
Journal:  Biochim Biophys Acta       Date:  2013-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.